{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T16:05:15Z","timestamp":1789574715352,"version":"build-2803163510"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,16]]},"DOI":"10.7759\/cureus.116354","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T15:10:16Z","timestamp":1789571416000},"source":"Crossref","is-referenced-by-count":0,"title":["Zileuton Beyond Asthma: A Multifaceted 5-Lipoxygenase Inhibitor With Emerging Therapeutic Potential Across Inflammation, Cancer, Neuroprotection, and Fibrosis"],"prefix":"10.7759","author":[{"given":"Victor D","family":"Ivancev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Iskander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran","family":"Ghotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clark","family":"Iorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana V","family":"Ivancev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Zileuton [Internet]. U.S. National Library of Medicine","author":"Bouchette D","year":"2024","unstructured":"Bouchette D. Zileuton [Internet]. U.S. National Library of Medicine. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2024."},{"key":"ref2","article-title":"5-lipoxygenase inhibitory activity of zileuton","volume":"256","author":"Carter GW","year":"1991","unstructured":"Carter GW, Young PR, Albert DH, et al.. 5-lipoxygenase inhibitory activity of zileuton. J Pharmacol Exp Ther. 1991, 256:929-37.","journal-title":"J Pharmacol Exp Ther"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M017822","article-title":"COX-2-dependent and -independent biosynthesis of dihydroxy-arachidonic acids in activated human leukocytes","volume":"53","author":"Tejera N","year":"2012","unstructured":"Tejera N, Boeglin WE, Suzuki T, Schneider C. COX-2-dependent and -independent biosynthesis of dihydroxy-arachidonic acids in activated human leukocytes. J Lipid Res. 2012, 53:87-94. 10.1194\/jlr.M017822","journal-title":"J Lipid Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra071371","article-title":"Leukotrienes","volume":"357","author":"Peters-Golden M","year":"2007","unstructured":"Peters-Golden M, Henderson WR Jr. Leukotrienes. N Engl J Med. 2007, 357:1841-54. 10.1056\/NEJMra071371","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1172\/JCI97945","article-title":"Leukotriene biosynthetic enzymes as therapeutic targets","volume":"128","author":"Haeggstr\u00f6m JZ","year":"2018","unstructured":"Haeggstr\u00f6m JZ. Leukotriene biosynthetic enzymes as therapeutic targets. J Clin Invest. 2018, 128:2680-90. 10.1172\/JCI97945","journal-title":"J Clin Invest"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-020-00324-8","article-title":"Ferroptosis: mechanisms, biology and role in disease","volume":"22","author":"Jiang X","year":"2021","unstructured":"Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 2021, 22:266-82. 10.1038\/s41580-020-00324-8","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/s40413-016-0131-2","article-title":"Asthma heterogeneity and severity","volume":"9","author":"Carr TF","year":"2016","unstructured":"Carr TF, Bleecker E. Asthma heterogeneity and severity. World Allergy Organ J. 2016, 9:41. 10.1186\/s40413-016-0131-2","journal-title":"World Allergy Organ J"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1378\/chest.111.2_supplement.27s","article-title":"Leukotrienes in the pathogenesis of asthma","volume":"111","author":"O'Byrne PM","year":"1997","unstructured":"O'Byrne PM. Leukotrienes in the pathogenesis of asthma. Chest. 1997, 111:27S-34S. 10.1378\/chest.111.2_supplement.27s","journal-title":"Chest"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-119-11-199312010-00001","article-title":"The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma","volume":"119","author":"Israel E","year":"1993","unstructured":"Israel E, Rubin P, Kemp JP, et al.. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Intern Med. 1993, 119:1059-66. 10.7326\/0003-4819-119-11-199312010-00001","journal-title":"Ann Intern Med"},{"key":"ref10","doi-asserted-by":"crossref","DOI":"10.1001\/jama.1996.03530360041036","article-title":"Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group","volume":"275","author":"Israel E","year":"1996","unstructured":"Israel E, Cohn J, Dub\u00e9 L, Drazen JM. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group. JAMA. 1996, 275:931-6.","journal-title":"JAMA"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/s0091-6749(96)80002-9","article-title":"Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial","volume":"98","author":"Liu MC","year":"1996","unstructured":"Liu MC, Dub\u00e9 LM, Lancaster J. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. J Allergy Clin Immunol. 1996, 98:859-71. 10.1016\/s0091-6749(96)80002-9","journal-title":"J Allergy Clin Immunol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.157.4.9707089","article-title":"Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics","volume":"157","author":"Dahl\u00e9n B","year":"1998","unstructured":"Dahl\u00e9n B, Nizankowska E, Szczeklik A, et al.. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am J Respir Crit Care Med. 1998, 157:1187-94. 10.1164\/ajrccm.157.4.9707089","journal-title":"Am J Respir Crit Care Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.10.003","article-title":"2020 focused updates to the asthma management guidelines: a report from the National Asthma Education and Prevention Program coordinating committee expert panel working group","volume":"146","author":"Cloutier MM","year":"2020","unstructured":"Cloutier MM, Baptist AP, Blake KV, et al.. 2020 focused updates to the asthma management guidelines: a report from the National Asthma Education and Prevention Program coordinating committee expert panel working group. J Allergy Clin Immunol. 2020, 146:1217-70. 10.1016\/j.jaci.2020.10.003","journal-title":"J Allergy Clin Immunol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.31.11.1352","article-title":"Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor","volume":"31","author":"Lu P","year":"2003","unstructured":"Lu P, Schrag ML, Slaughter DE, Raab CE, Shou M, Rodrigues AD. Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab Dispos. 2003, 31:1352-60. 10.1124\/dmd.31.11.1352","journal-title":"Drug Metab Dispos"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2147\/copd.s4854","article-title":"Change in inflammation in out-patient COPD patients from stable phase to a subsequent exacerbation","volume":"4","author":"Bathoorn E","year":"2009","unstructured":"Bathoorn E, Liesker JJ, Postma DS, et al.. Change in inflammation in out-patient COPD patients from stable phase to a subsequent exacerbation. Int J Chron Obstruct Pulmon Dis. 2009, 4:101-9. 10.2147\/copd.s4854","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1042\/CS20160487","article-title":"Cellular and molecular mechanisms of asthma and COPD","volume":"131","author":"Barnes PJ","year":"2017","unstructured":"Barnes PJ. Cellular and molecular mechanisms of asthma and COPD. Clin Sci (Lond). 2017, 131:1541-58. 10.1042\/CS20160487","journal-title":"Clin Sci (Lond)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3109\/15412555.2010.540273","article-title":"Randomized trial of zileuton for treatment of COPD exacerbations requiring hospitalization","volume":"8","author":"Woodruff PG","year":"2011","unstructured":"Woodruff PG, Albert RK, Bailey WC, et al.. Randomized trial of zileuton for treatment of COPD exacerbations requiring hospitalization. COPD. 2011, 8:21-9. 10.3109\/15412555.2010.540273","journal-title":"COPD"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1378\/chest.123.4.1240","article-title":"Neutrophil chemotactic activity of sputum from patients with COPD: role of interleukin 8 and leukotriene B4","volume":"123","author":"Beeh KM","year":"2003","unstructured":"Beeh KM, Kornmann O, Buhl R, Culpitt SV, Giembycz MA, Barnes PJ. Neutrophil chemotactic activity of sputum from patients with COPD: role of interleukin 8 and leukotriene B4. Chest. 2003, 123:1240-7. 10.1378\/chest.123.4.1240","journal-title":"Chest"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/s0016-5085(84)80015-3","article-title":"Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease","volume":"86","author":"Sharon P","year":"1984","unstructured":"Sharon P, Stenson WF. Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease. Gastroenterology. 1984, 86:453-60. 10.1016\/s0016-5085(84)80015-3","journal-title":"Gastroenterology"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/gut.39.2.248","article-title":"Mucosal factors inducing neutrophil movement in ulcerative colitis: the role of interleukin 8 and leukotriene B4","volume":"39","author":"Cole AT","year":"1996","unstructured":"Cole AT, Pilkington BJ, McLaughlan J, Smith C, Balsitis M, Hawkey CJ. Mucosal factors inducing neutrophil movement in ulcerative colitis: the role of interleukin 8 and leukotriene B4. Gut. 1996, 39:248-54. 10.1136\/gut.39.2.248","journal-title":"Gut"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)90803-d","article-title":"Selective 5-lipoxygenase inhibition in ulcerative colitis","volume":"335","author":"Staerk Laursen L","year":"1990","unstructured":"Staerk Laursen L, Lauritsen K, Naesdal J, Rask-Madsen J, Bukhave K. Selective 5-lipoxygenase inhibition in ulcerative colitis. Lancet. 1990, 335:683-5. 10.1016\/0140-6736(90)90803-d","journal-title":"Lancet"},{"key":"ref22","article-title":"Phase II study of the safety and efficacy of a 5-lipoxygenase inhibitor in patients with ulcerative colitis","volume":"87","author":"Collawn C","year":"1992","unstructured":"Collawn C, Rubin P, Perez N, et al.. Phase II study of the safety and efficacy of a 5-lipoxygenase inhibitor in patients with ulcerative colitis. Am J Gastroenterol. 1992, 87:342-6.","journal-title":"Am J Gastroenterol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1997.v112.pm9041232","article-title":"A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis. The European Zileuton Study Group For Ulcerative Colitis","volume":"112","author":"Hawkey CJ","year":"1997","unstructured":"Hawkey CJ, Dube LM, Rountree LV, Linnen PJ, Lancaster JF. A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis. The European Zileuton Study Group For Ulcerative Colitis. Gastroenterology. 1997, 112:718-24. 10.1053\/gast.1997.v112.pm9041232","journal-title":"Gastroenterology"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2017.38","article-title":"Mechanisms of hepatic stellate cell activation","volume":"14","author":"Tsuchida T","year":"2017","unstructured":"Tsuchida T, Friedman SL. Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol. 2017, 14:397-411. 10.1038\/nrgastro.2017.38","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.107.128264","article-title":"Comparative protection against liver inflammation and fibrosis by a selective cyclooxygenase-2 inhibitor and a nonredox-type 5-lipoxygenase inhibitor","volume":"323","author":"Horrillo R","year":"2007","unstructured":"Horrillo R, Planagum\u00e0 A, Gonz\u00e1lez-P\u00e9riz A, et al.. Comparative protection against liver inflammation and fibrosis by a selective cyclooxygenase-2 inhibitor and a nonredox-type 5-lipoxygenase inhibitor. J Pharmacol Exp Ther. 2007, 323:778-86. 10.1124\/jpet.107.128264","journal-title":"J Pharmacol Exp Ther"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.628583","article-title":"Inhibition of 5-lipoxygenase in hepatic stellate cells alleviates liver fibrosis","volume":"12","author":"Pu S","year":"2021","unstructured":"Pu S, Li Y, Liu Q, et al.. Inhibition of 5-lipoxygenase in hepatic stellate cells alleviates liver fibrosis. Front Pharmacol. 2021, 12:628583. 10.3389\/fphar.2021.628583","journal-title":"Front Pharmacol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.22038\/IJBMS.2017.9482","article-title":"Inhibition of 5-lipoxygenase inhibitor zileuton in high-fat diet-induced nonalcoholic fatty liver disease progression model","volume":"20","author":"Ma K","year":"2017","unstructured":"Ma K, Chen Y, Liang X, Miao J, Zhao Q. Inhibition of 5-lipoxygenase inhibitor zileuton in high-fat diet-induced nonalcoholic fatty liver disease progression model. Iran J Basic Med Sci. 2017, 20:1207-12. 10.22038\/IJBMS.2017.9482","journal-title":"Iran J Basic Med Sci"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200730090-00006","article-title":"Clinical pattern of zileuton-associated liver injury: results of a 12-month study in patients with chronic asthma","volume":"30","author":"Watkins PB","year":"2007","unstructured":"Watkins PB, Dube LM, Walton-Bowen K, Cameron CM, Kasten LE. Clinical pattern of zileuton-associated liver injury: results of a 12-month study in patients with chronic asthma. Drug Saf. 2007, 30:805-15. 10.2165\/00002018-200730090-00006","journal-title":"Drug Saf"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.4062\/biomolther.2023.062","article-title":"Synergistic renoprotective effect of melatonin and zileuton by inhibition of ferroptosis via the AKT\/mTOR\/NRF2 signaling in kidney injury and fibrosis","volume":"31","author":"Jung KH","year":"2023","unstructured":"Jung KH, Kim SE, Go HG, et al.. Synergistic renoprotective effect of melatonin and zileuton by inhibition of ferroptosis via the AKT\/mTOR\/NRF2 signaling in kidney injury and fibrosis. Biomol Ther (Seoul). 2023, 31:599-610. 10.4062\/biomolther.2023.062","journal-title":"Biomol Ther (Seoul)"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkad246","article-title":"Zileuton ameliorates aminoglycoside and polymyxin-associated acute kidney injury in an animal model","volume":"78","author":"Hudson CS","year":"2023","unstructured":"Hudson CS, Smith JE, Eales BM, Kajiji S, Liu X, Truong LD, Tam VH. Zileuton ameliorates aminoglycoside and polymyxin-associated acute kidney injury in an animal model. J Antimicrob Chemother. 2023, 78:2435-41. 10.1093\/jac\/dkad246","journal-title":"J Antimicrob Chemother"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00287-25","article-title":"Drug development studies supporting zileuton as a parenteral adjuvant to attenuate antibiotic-associated nephrotoxicity","volume":"69","author":"Hudson CS","year":"2025","unstructured":"Hudson CS, Smith JE, Vuong LT, et al.. Drug development studies supporting zileuton as a parenteral adjuvant to attenuate antibiotic-associated nephrotoxicity. Antimicrob Agents Chemother. 2025, 69:e0028725. 10.1128\/aac.00287-25","journal-title":"Antimicrob Agents Chemother"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen JS","year":"2016","unstructured":"Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016, 388:2023-38. 10.1016\/s0140-6736(16)30173-8","journal-title":"Lancet"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2009.82","article-title":"Tyrosine kinases as targets for the treatment of rheumatoid arthritis","volume":"5","author":"D'Aura Swanson C","year":"2009","unstructured":"D'Aura Swanson C, Paniagua RT, Lindstrom TM, Robinson WH. Tyrosine kinases as targets for the treatment of rheumatoid arthritis. Nat Rev Rheumatol. 2009, 5:317-24. 10.1038\/nrrheum.2009.82","journal-title":"Nat Rev Rheumatol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1007\/BF00923346","article-title":"Relationship between leukotriene B4 and immunological parameters in rheumatoid synovial fluids","volume":"15","author":"Ahmadzadeh N","year":"1991","unstructured":"Ahmadzadeh N, Shingu M, Nobunaga M, Tawara T. Relationship between leukotriene B4 and immunological parameters in rheumatoid synovial fluids. Inflammation. 1991, 15:497-503. 10.1007\/BF00923346","journal-title":"Inflammation"},{"key":"ref35","article-title":"Zileuton, a 5-lipoxygenase inhibitor in rheumatoid arthritis","volume":"19","author":"Weinblatt ME","year":"1992","unstructured":"Weinblatt ME, Kremer JM, Coblyn JS, et al.. Zileuton, a 5-lipoxygenase inhibitor in rheumatoid arthritis. J Rheumatol. 1992, 19:1537-41.","journal-title":"J Rheumatol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18020236","article-title":"Cross-talk between cancer cells and the tumour microenvironment: the role of the 5-lipoxygenase pathway","volume":"18","author":"Moore GY","year":"2017","unstructured":"Moore GY, Pidgeon GP. Cross-talk between cancer cells and the tumour microenvironment: the role of the 5-lipoxygenase pathway. Int J Mol Sci. 2017, 18:236. 10.3390\/ijms18020236","journal-title":"Int J Mol Sci"},{"key":"ref37","article-title":"Expression of lipoxygenase in human prostate cancer and growth reduction by its inhibitors","volume":"24","author":"Matsuyama M","year":"2004","unstructured":"Matsuyama M, Yoshimura R, Mitsuhashi M, et al.. Expression of lipoxygenase in human prostate cancer and growth reduction by its inhibitors. Int J Oncol. 2004, 24:821-7.","journal-title":"Int J Oncol"},{"key":"ref38","article-title":"Chemoprevention by lipoxygenase and leukotriene pathway inhibitors of vinyl carbamate-induced lung tumors in mice","volume":"62","author":"Gunning WT","year":"2002","unstructured":"Gunning WT, Kramer PM, Steele VE, Pereira MA. Chemoprevention by lipoxygenase and leukotriene pathway inhibitors of vinyl carbamate-induced lung tumors in mice. Cancer Res. 2002, 62:4199-201.","journal-title":"Cancer Res"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14122893","article-title":"Clinical study of aspirin and zileuton on biomarkers of tobacco-related carcinogenesis in current smokers","volume":"14","author":"Garland LL","year":"2022","unstructured":"Garland LL, Guillen-Rodriguez J, Hsu CH, et al.. Clinical study of aspirin and zileuton on biomarkers of tobacco-related carcinogenesis in current smokers. Cancers (Basel). 2022, 14:2893. 10.3390\/cancers14122893","journal-title":"Cancers (Basel)"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4631","article-title":"Overexpression of 5-lipoxygenase in colon polyps and cancer and the effect of 5-LOX inhibitors in vitro and in a murine model","volume":"14","author":"Melstrom LG","year":"2008","unstructured":"Melstrom LG, Bentrem DJ, Salabat MR, et al.. Overexpression of 5-lipoxygenase in colon polyps and cancer and the effect of 5-LOX inhibitors in vitro and in a murine model. Clin Cancer Res. 2008, 14:6525-30. 10.1158\/1078-0432.CCR-07-4631","journal-title":"Clin Cancer Res"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0121402","article-title":"Zileuton, 5-lipoxygenase inhibitor, acts as a chemopreventive agent in intestinal polyposis, by modulating polyp and systemic inflammation","volume":"10","author":"Gounaris E","year":"2015","unstructured":"Gounaris E, Heiferman MJ, Heiferman JR, et al.. Zileuton, 5-lipoxygenase inhibitor, acts as a chemopreventive agent in intestinal polyposis, by modulating polyp and systemic inflammation. PLoS One. 2015, 10:e0121402. 10.1371\/journal.pone.0121402","journal-title":"PLoS One"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2006.08.006","article-title":"Sj\u00f6gren-Larsson syndrome: molecular genetics and biochemical pathogenesis of fatty aldehyde dehydrogenase deficiency","volume":"90","author":"Rizzo WB","year":"2007","unstructured":"Rizzo WB. Sj\u00f6gren-Larsson syndrome: molecular genetics and biochemical pathogenesis of fatty aldehyde dehydrogenase deficiency. Mol Genet Metab. 2007, 90:1-9. 10.1016\/j.ymgme.2006.08.006","journal-title":"Mol Genet Metab"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-510x(00)00474-3","article-title":"Defective metabolism of leukotriene B4 in the Sj\u00f6gren-Larsson syndrome","volume":"183","author":"Willemsen MAAP","year":"2001","unstructured":"Willemsen MAAP, Rotteveel JJ, de Jong JGN, et al.. Defective metabolism of leukotriene B4 in the Sj\u00f6gren-Larsson syndrome. J Neurol Sci. 2001, 183:61-7. 10.1016\/s0022-510x(00)00474-3","journal-title":"J Neurol Sci"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1055\/s-2000-15288","article-title":"5-Lipoxygenase inhibition: a new treatment strategy for Sj\u00f6gren-Larsson syndrome","volume":"31","author":"Willemsen MA","year":"2000","unstructured":"Willemsen MA, Rotteveel JJ, Steijlen PM, Heerschap A, Mayatepek E. 5-Lipoxygenase inhibition: a new treatment strategy for Sj\u00f6gren-Larsson syndrome. Neuropediatrics. 2000, 31:1-3. 10.1055\/s-2000-15288","journal-title":"Neuropediatrics"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1007\/s004310100838","article-title":"Clinical and biochemical effects of zileuton in patients with the Sj\u00f6gren-Larsson syndrome","volume":"160","author":"Willemsen MA","year":"2001","unstructured":"Willemsen MA, Lutt MA, Steijlen PM, et al.. Clinical and biochemical effects of zileuton in patients with the Sj\u00f6gren-Larsson syndrome. Eur J Pediatr. 2001, 160:711-7. 10.1007\/s004310100838","journal-title":"Eur J Pediatr"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2195","article-title":"Zileuton for pruritus in Sj\u00f6gren-Larsson syndrome: a randomized double-blind placebo-controlled crossover trial","volume":"96","author":"Fuijkschot J","year":"2016","unstructured":"Fuijkschot J, Seyger MM, Bastiaans DE, Wevers RA, Roeleveld N, Willemsen MA. Zileuton for pruritus in Sj\u00f6gren-Larsson syndrome: a randomized double-blind placebo-controlled crossover trial. Acta Derm Venereol. 2016, 96:255-6. 10.2340\/00015555-2195","journal-title":"Acta Derm Venereol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.5966\/sctm.2015-0381","article-title":"Concise review: bridging the gap: novel neuroregenerative and neuroprotective strategies in spinal cord injury","volume":"5","author":"Ahuja CS","year":"2016","unstructured":"Ahuja CS, Fehlings M. Concise review: bridging the gap: novel neuroregenerative and neuroprotective strategies in spinal cord injury. Stem Cells Transl Med. 2016, 5:914-24. 10.5966\/sctm.2015-0381","journal-title":"Stem Cells Transl Med"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines8100389","article-title":"Revisiting traumatic brain injury: from molecular mechanisms to therapeutic interventions","volume":"8","author":"Jarrahi A","year":"2020","unstructured":"Jarrahi A, Braun M, Ahluwalia M, et al.. Revisiting traumatic brain injury: from molecular mechanisms to therapeutic interventions. Biomedicines. 2020, 8:389. 10.3390\/biomedicines8100389","journal-title":"Biomedicines"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0707577","article-title":"Effects of zileuton and montelukast in mouse experimental spinal cord injury","volume":"153","author":"Genovese T","year":"2008","unstructured":"Genovese T, Rossi A, Mazzon E, et al.. Effects of zileuton and montelukast in mouse experimental spinal cord injury. Br J Pharmacol. 2008, 153:568-82. 10.1038\/sj.bjp.0707577","journal-title":"Br J Pharmacol"},{"key":"ref50","article-title":"Zileuton ameliorates neuronal ferroptosis and functional recovery after spinal cord injury","volume":"29","author":"Sun P","year":"2023","unstructured":"Sun P, Zhou J, Zhao T, Qi H, Qian G. Zileuton ameliorates neuronal ferroptosis and functional recovery after spinal cord injury. Altern Ther Health Med. 2023, 29:314-9.","journal-title":"Altern Ther Health Med"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1516836","article-title":"Zileuton protects against arachidonic acid\/5-lipoxygenase\/leukotriene axis-mediated neuroinflammation in experimental traumatic brain injury","volume":"16","author":"Xu X","year":"2025","unstructured":"Xu X, Wang Y, Li X, et al.. Zileuton protects against arachidonic acid\/5-lipoxygenase\/leukotriene axis-mediated neuroinflammation in experimental traumatic brain injury. Front Pharmacol. 2025, 16:1516836. 10.3389\/fphar.2025.1516836","journal-title":"Front Pharmacol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0707530","article-title":"Pathophysiology of ischaemic stroke: insights from imaging, and implications for therapy and drug discovery","volume":"153 Suppl 1","author":"Moustafa RR","year":"2008","unstructured":"Moustafa RR, Baron JC. Pathophysiology of ischaemic stroke: insights from imaging, and implications for therapy and drug discovery. Br J Pharmacol. 2008, 153 Suppl 1:S44-54. 10.1038\/sj.bjp.0707530","journal-title":"Br J Pharmacol"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2006.05.022","article-title":"Spatio-temporal properties of 5-lipoxygenase expression and activation in the brain after focal cerebral ischemia in rats","volume":"79","author":"Zhou Y","year":"2006","unstructured":"Zhou Y, Wei EQ, Fang SH, et al.. Spatio-temporal properties of 5-lipoxygenase expression and activation in the brain after focal cerebral ischemia in rats. Life Sci. 2006, 79:1645-56. 10.1016\/j.lfs.2006.05.022","journal-title":"Life Sci"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-019-00787-4","article-title":"Early and sustained increases in leukotriene B(4) levels are associated with poor clinical outcome in ischemic stroke patients","volume":"17","author":"Chan SJ","year":"2020","unstructured":"Chan SJ, Ng MP, Zhao H, Ng GJ, De Foo C, Wong PT, Seet RC. Early and sustained increases in leukotriene B(4) levels are associated with poor clinical outcome in ischemic stroke patients. Neurotherapeutics. 2020, 17:282-93. 10.1007\/s13311-019-00787-4","journal-title":"Neurotherapeutics"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1179\/174313209X403913","article-title":"5-lipoxygenase inhibitor zileuton attenuates ischemic brain damage: involvement of matrix metalloproteinase 9","volume":"31","author":"Tu XK","year":"2009","unstructured":"Tu XK, Yang WZ, Shi SS, Chen CM, Wang CH. 5-lipoxygenase inhibitor zileuton attenuates ischemic brain damage: involvement of matrix metalloproteinase 9. Neurol Res. 2009, 31:848-52. 10.1179\/174313209X403913","journal-title":"Neurol Res"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.21-19-07724.2001","article-title":"Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia","volume":"21","author":"Asahi M","year":"2001","unstructured":"Asahi M, Wang X, Mori T, et al.. Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J Neurosci. 2001, 21:7724-32. 10.1523\/JNEUROSCI.21-19-07724.2001","journal-title":"J Neurosci"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-010-9191-6","article-title":"Zileuton reduces inflammatory reaction and brain damage following permanent cerebral ischemia in rats","volume":"33","author":"Tu XK","year":"2010","unstructured":"Tu XK, Yang WZ, Wang CH, et al.. Zileuton reduces inflammatory reaction and brain damage following permanent cerebral ischemia in rats. Inflammation. 2010, 33:344-52. 10.1007\/s10753-010-9191-6","journal-title":"Inflammation"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-013-9657-4","article-title":"5-Lipoxygenase inhibitor zileuton inhibits neuronal apoptosis following focal cerebral ischemia","volume":"36","author":"Shi SS","year":"2013","unstructured":"Shi SS, Yang WZ, Tu XK, Wang CH, Chen CM, Chen Y. 5-Lipoxygenase inhibitor zileuton inhibits neuronal apoptosis following focal cerebral ischemia. Inflammation. 2013, 36:1209-17. 10.1007\/s10753-013-9657-4","journal-title":"Inflammation"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-018-0001-z","article-title":"Atopic dermatitis","volume":"4","author":"Weidinger S","year":"2018","unstructured":"Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Primers. 2018, 4:1. 10.1038\/s41572-018-0001-z","journal-title":"Nat Rev Dis Primers"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(89)90132-2","article-title":"Eicosanoids in skin of patients with atopic dermatitis: prostaglandin E2 and leukotriene B4 are present in biologically active concentrations","volume":"83","author":"Fogh K","year":"1989","unstructured":"Fogh K, Herlin T, Kragballe K. Eicosanoids in skin of patients with atopic dermatitis: prostaglandin E2 and leukotriene B4 are present in biologically active concentrations. J Allergy Clin Immunol. 1989, 83:450-5. 10.1016\/0091-6749(89)90132-2","journal-title":"J Allergy Clin Immunol"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1016\/s1081-1206(10)62868-2","article-title":"A pilot study examining the role of zileuton in atopic dermatitis","volume":"83","author":"Woodmansee DP","year":"1999","unstructured":"Woodmansee DP, Simon RA. A pilot study examining the role of zileuton in atopic dermatitis. Ann Allergy Asthma Immunol. 1999, 83:548-52. 10.1016\/s1081-1206(10)62868-2","journal-title":"Ann Allergy Asthma Immunol"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.06.427","article-title":"Q301 (Zileuton) cream demonstrates superiority to vehicle in improving atopic dermatitis: results from a Phase 2A trial","volume":"81","author":"Fleischer A","year":"2019","unstructured":"Fleischer A, Nam K, Kim J, et al.. Q301 (Zileuton) cream demonstrates superiority to vehicle in improving atopic dermatitis: results from a Phase 2A trial. J Am Acad Dermatol. 2019, 81:AB112. 10.1016\/j.jaad.2019.06.427","journal-title":"J Am Acad Dermatol"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.29","article-title":"Acne vulgaris","volume":"1","author":"Moradi Tuchayi S","year":"2015","unstructured":"Moradi Tuchayi S, Makrantonaki E, Ganceviciene R, Dessinioti C, Feldman SR, Zouboulis CC. Acne vulgaris. Nat Rev Dis Primers. 2015, 1:15029. 10.1038\/nrdp.2015.29","journal-title":"Nat Rev Dis Primers"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-005-0715-8","article-title":"Enzymes involved in the biosynthesis of leukotriene B4 and prostaglandin E2 are active in sebaceous glands","volume":"84","author":"Alestas T","year":"2006","unstructured":"Alestas T, Ganceviciene R, Fimmel S, M\u00fcller-Decker K, Zouboulis CC. Enzymes involved in the biosynthesis of leukotriene B4 and prostaglandin E2 are active in sebaceous glands. J Mol Med (Berl). 2006, 84:75-87. 10.1007\/s00109-005-0715-8","journal-title":"J Mol Med (Berl)"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.2009.00929.x","article-title":"Zileuton prevents the activation of the leukotriene pathway and reduces sebaceous lipogenesis","volume":"19","author":"Zouboulis CC","year":"2010","unstructured":"Zouboulis CC, Seltmann H, Alestas T. Zileuton prevents the activation of the leukotriene pathway and reduces sebaceous lipogenesis. Exp Dermatol. 2010, 19:148-50. 10.1111\/j.1600-0625.2009.00929.x","journal-title":"Exp Dermatol"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1159\/000081481","article-title":"Zileuton, an oral 5-lipoxygenase inhibitor, directly reduces sebum production","volume":"210","author":"Zouboulis ChC","year":"2005","unstructured":"Zouboulis ChC, Saborowski A, Boschnakow A. Zileuton, an oral 5-lipoxygenase inhibitor, directly reduces sebum production. Dermatology. 2005, 210:36-8. 10.1159\/000081481","journal-title":"Dermatology"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.4161\/derm.1.3.8368","article-title":"Zileuton, a new efficient and safe systemic anti-acne drug","volume":"1","author":"Zouboulis CC","year":"2009","unstructured":"Zouboulis CC. Zileuton, a new efficient and safe systemic anti-acne drug. Dermatoendocrinol. 2009, 1:188-92. 10.4161\/derm.1.3.8368","journal-title":"Dermatoendocrinol"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.12.017","article-title":"Guidelines of care for the management of acne vulgaris","volume":"90","author":"Reynolds RV","year":"2024","unstructured":"Reynolds RV, Yeung H, Cheng CE, et al.. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2024, 90:1006.e1-e30. 10.1016\/j.jaad.2023.12.017","journal-title":"J Am Acad Dermatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/532127-zileuton-beyond-asthma-a-multifaceted-5-lipoxygenase-inhibitor-with-emerging-therapeutic-potential-across-inflammation-cancer-neuroprotection-and-fibrosis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T15:10:18Z","timestamp":1789571418000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/532127-zileuton-beyond-asthma-a-multifaceted-5-lipoxygenase-inhibitor-with-emerging-therapeutic-potential-across-inflammation-cancer-neuroprotection-and-fibrosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":68,"URL":"https:\/\/doi.org\/10.7759\/cureus.116354","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,16]]}}}